Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
Boehringer Ingelheim's Phase III spesolimab trial leads a small PG pipeline shaped by IL-36, IL-23/IL-17 and complement research, as InflaRx's vilobelimab program stalls.Dublin, Oct. (GLOBE NEWSWIRE) ...
The study pointed to TNF blockade as a potential therapeutic option for patients with OTULIN-related pyoderma gangrenosum. The investigators noted that one patient, whose painful skin sores were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results